CNS Cluster Addiction Drug Development Pipeline to Feature Mu and Kappa Opioid Receptors as Dominant Molecular Target

Published Date : May 29, 2017

ALBANY, New York, May 29, 2017 – The central nervous system (CNS) addiction cluster report added by has been expected to be a fine study of the CNS cluster pipeline landscape. Titled “CNS Cluster Addiction Drug Development Pipeline Review, 2017,” the report starts off with a guidance section that includes a to-the-point executive summary. The authors of the report have foreseen the pipeline sizes to range from 67 in drug addiction and 19 in nicotine addiction. There could be an extensive notch of overlap between these indicators in respect of top participants and the varieties of molecular target under study, according to the report. 

The researchers have analyzed dopamine and cannabinoid neurotransmitter receptors to be common molecular targets across the three major types of addiction, viz. opioid, drug, and alcohol. Opioid receptors such as kappa (?) and mu (?) have been studied to a superior molecular target across the three addiction types. 

The report offers a brilliant coverage of CNS cluster addiction followed by a comprehensive explanation of key details about opioid addiction, nicotine addiction, drug addiction, and alcohol addiction. It has been expected on the part of readers to access a comprehensive commentary on the therapeutics under development. Readers could also be enlightened about top players involved in the development of therapeutics for opioid addiction, nicotine addiction, drug addiction, and alcohol addiction. Besides this, the report provides critical information about discontinued products and dormant projects. 

For Sample Copy, click here: 

Under the scope of the report, interested parties could be provided with a detailed data on the most active firms involved in the addiction therapeutics pipeline. Other kinds of information such as the most prominent of all pharmaceutical approaches at different stages of the pipeline and for each indication have also been provided in the report. Players operating within the CNS addiction cluster pipeline could be able to gauge the magnitude of the role played by institutions and universities in comparison with pharmaceutical firms. 

The report has revealed the most significant research and development data publications and milestones related to the sphere of addiction therapeutics. Buyers of the report have been anticipated to access an insightful account of the overall CNS addiction cluster pipeline. The report offers an at-a-glance and general idea about the different types of therapeutic development products for various indications. Apart from a summary of the latest information on several individual pipeline programs considering each indication, buyers have been envisaged to receive a comprehensive overview of recent milestones and updates about each program. Buyers will also be able to examine products under development in granular detail.

The publication has analyzed several universities, institutions, and companies that are presently operating in the CNS addiction cluster pipeline, including products fielded by them. On the basis of route of administration, mechanism of action, molecular target, and molecular type, the publication helps to comprehend the composition of the CNS addiction cluster pipeline. 

To order report Call Toll Free: 866-997-4948 or send an email on